Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: February 2019

How oncologists view leadership in ImmunoOncology

In our latest release from the 2019 Leadership study, we reveal 7 key attributes that account for 75% of Oncologists’ definition of leadership in ImmunoOncology (IO).

Oncology Leadership Factors

Click on image to enlarge

These attributes comprise R&D / pipeline and product related aspects of life science company activities.

We found high consistency across geography. However, EU oncologists placed greater emphasis on “clinical trials & research grants” and “integration of biomarkers and diagnostics” compared to their US colleagues.

The attributes are in order of overall impact:

  1. Number of approvals (cancer types & lines of therapy)
  2. Number of different IO products available within portfolio
  3. Development of combination therapies with IO
  4. Clinical trials and research grants
  5. Integration of biomarkers and diagnostics
  6. Differentiation from other IO offerings
  7. Value proposition of product portfolio

For each of these attributes we analyze performance by life science companies. Get in touch to find out how your company and your competitors performed.

In our next release, we will explore the remaining attributes and reveal the relative importance of specific commercial and marketing activities to oncologists when defining leadership.

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service. The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

2019 Leadership Study in Oncology & ImmunoOncology

Later this month, MDoutlook will release results from the latest wave of their global leadership study.

Using ONCpulse™, we engaged with a robust sample of oncologists located in the United States and Europe. The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Early results reveal the top 3 companies in Oncology and ImmunoOncology. Oncology Leadership Top 3

Across tumor types, BMS were rated as the top ImmunoOncology leader in 9 out of the 12 areas covered. Oncologists favored Roche & Merck highest in breast cancer (Roche); bladder cancer (Roche & Merck) and NSCLC (Merck).

ImmunoOncology Leadership across tumors

Oncologists chose to rate leadership across a greater number of companies in the broader oncology arena compared to a tighter list of companies they rated in ImmunoOncology.

Seventy percent of US oncologists viewed leadership success across tumor types than in any one specific area (30% respondents). This view was stronger when compared to the split picture (49% vs 51% respectively) presented by EU-based oncologists.

More information about the 2019 Leadership Study will become available as we publish the read-out results. Please contact us if you wish to be included in the distribution of the study.